FY2024 Earnings Estimate for BioAtla Issued By HC Wainwright

BioAtla, Inc. (NASDAQ:BCAB) – Stock analysts at HC Wainwright issued their FY2024 earnings estimates for shares of BioAtla in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst A. He anticipates that the company will post earnings of ($1.46) per share for the year. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for BioAtla’s current full-year earnings is ($1.52) per share. HC Wainwright also issued estimates for BioAtla’s Q4 2024 earnings at ($0.33) EPS, Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.34) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.40) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($1.29) EPS and FY2028 earnings at ($0.99) EPS.

BioAtla (NASDAQ:BCAB) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.12. The firm had revenue of $11.00 million for the quarter. During the same period in the prior year, the company earned ($0.70) earnings per share.

Separately, JMP Securities reiterated a “market outperform” rating and issued a $5.00 price objective on shares of BioAtla in a research report on Monday, September 16th.

BioAtla Trading Down 14.1 %

Shares of BCAB stock opened at $1.71 on Friday. BioAtla has a 12-month low of $1.14 and a 12-month high of $4.02. The company has a market cap of $82.66 million, a price-to-earnings ratio of -1.01 and a beta of 1.03. The stock has a 50 day simple moving average of $1.92 and a 200-day simple moving average of $1.88.

Hedge Funds Weigh In On BioAtla

A number of institutional investors have recently added to or reduced their stakes in BCAB. Vontobel Holding Ltd. acquired a new position in BioAtla in the third quarter worth $28,000. Ground Swell Capital LLC acquired a new position in shares of BioAtla in the 2nd quarter valued at about $33,000. Valmark Advisers Inc. bought a new stake in shares of BioAtla during the 2nd quarter valued at about $34,000. Rinkey Investments acquired a new stake in BioAtla during the second quarter worth about $35,000. Finally, Chicago Partners Investment Group LLC acquired a new stake in BioAtla during the third quarter worth about $44,000. Institutional investors and hedge funds own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.